Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
FAIL · Does not pass the screen
106.20 USD
At the last full screen 2026-09-11
Screened 2026-09-11 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Dianthus Therapeutics, Inc. holds its Markdown at $106.20. Consolidating, no directional conviction, held for 4 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 4 days
Price at the screen
$106.20
Valuation
N/A trailing · -23.03 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.06
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.26%
Below 33%
Interest-bearing debt is just 0.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.74%
Below 33%
Cash held in interest-bearing accounts and securities is 20.7% of assets, under the one-third limit.
Pass
Receivables
9.63%
Below 49%
Money owed to the company is 9.6% of assets, under the 49% limit.
Pass
Revenue purity
791.70%
Below 5%
791.7% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 25.7% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +26% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage bet with zero profits today
Picture a lab team betting the house on one antibody tweak that might tame brutal autoimmune flares. That is the whole story at Dianthus right now. The shares sit below our calculated fair value, yet the opportunity rating stays at none because the business has not crossed into real revenue or positive returns.
The numbers tell the same tale. Revenue is shrinking fast, margins sit at zero, and return on equity is deeply negative. Twelve analysts still cluster around a strong buy with a median target matching our fair value, but those targets rest on future trial success that has not arrived. Ethical screen clears, yet that alone does not turn a pre-profit clinical programme into an investable business.
Risk sits in the usual biotech trap. One failed study or delayed approval can wipe years of value while cash keeps burning. Unknown competitive moat and negative forward earnings leave little margin for the inevitable setbacks. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DNTH trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-27Accumulation$112.11+6.2%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126. Insiders have been net sellers over the past quarter.
2026-07-26Accumulation$105.60+28.7%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 28.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126.
2026-07-18Accumulation$82.07+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 72% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 310%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (12 analysts) rates it strong buy, with a mean price target of $126.
2026-07-03Accumulation$82.07+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$82.07Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
